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Ampicillin has been shown to improve glucose tolerance in mice. We hypothesized that this effect is present only if treatment is
initiated prior to weaning and that it disappears when treatment is terminated. High-fat fed C57BL/6NTac mice were divided into
groups that received Ampicillin at different ages or not at all. We found that both diet and Ampicillin significantly changed the
gut microbiota composition in the animals. Furthermore, there was a significant improvement in glucose tolerance in Ampicillin-
treated, five-week-old mice compared to nontreated mice in the control group. At study termination, expressions of mRNA coding
for tumor necrosis factor, serum amyloid A, and lactase were upregulated, while the expression of tumor necrosis factor (ligand)
superfamily member 15 was downregulated in the ileum of Ampicillin-treated mice. Higher dendritic cell percentages were found
systemically in high-fat diet mice, and a lower tolerogenic dendritic cell percentage was found both in relation to high-fat diet and
late Ampicillin treatment. The results support our hypothesis that a “window” exists early in life in which an alteration of the gut
microbiota affects glucose tolerance as well as development of gut immunity and that this window may disappear after weaning.
1. Introduction
Type 2 diabetes (T2D) is an increasingly omnipresent disease
not only in the western world but also in many of the
fastest developing third world countries [1]. It is caused
by peripheral insulin resistance and an insulin production
unable to compensate [2]. During the past decade, gut
microbiota composition has been in focus to unravel the
enigma of such lifestyle diseases and their development [3]. In
animal models, gut microbiota composition has been shown
to influence the development of a variety of autoimmune and
inflammatory diseases such as type 1 and type 2 diabetes,
rheumatoid arthritis, atherosclerosis, inflammatory bowel
disease, and a range of allergies [4].
Leptin-deficient obese (lepob) mice that develop glucose
intolerance have a significant reduction in Bacteroidetes and
an increase in Firmicutes compared with their wild-type lean
litter mates [5]. Furthermore, the obese phenotype from lepob
mice may be transplanted with the gut microbiota to germ-
free wild-type mice [6]. Diet-induced obese (DIO) mice
also exhibit a modified composition of the gut microbiota,
endotoxemia, and an increased intestinal permeability [7].
Mechanistic explanations are still somewhat theoretical, and
theories range from decreased early priming of intestinal
regulatory T cells (Treg) leading to inadequate suppression
of T helper cells (Th) later in life—the so-called “Hygiene
Hypothesis” [8]—to transfer lipopolysaccharides (LPS) over
a leaky gut in sensitive individuals [9]. An essential role
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Figure 1: Experimental design for diet-induced obesity (DIO) and
Ampicillin treatment in C57BL/6mice.
of the gut microbiota is to facilitate energy harvest from
otherwise indigestible components in our diet. Therefore,
it is reasonable to assume that the gut microbiota has an
impact on gut lipid metabolism. The reconstitution of germ-
free mice with a normal microbiota increases total body fat
and leads to a greater capacity to harvest energy from the
diet and decreased insulin sensitivity [10]. Germ-free mice
compared with conventional mice show decreased lipogenic-
related gene expression [11]. However, several studies indicate
that mechanisms are more sophisticated than simply being
linked up to gut lipid metabolism. It has been hypothesized
that peripheral insulin resistance is augmented by stimulation
of intestinal Toll-like receptor 4 (TLR4) primarily by LPS
from Gram-negative Proteobacteria leading to secretion of
proinflammatory cytokines such as tumor necrosis factor
alpha (TNF
𝛼
). This has been exemplified by continuous sub-
cutaneous infusion of LPS in mice, which increases glycemia
and insulinemia and resulted in weight gain of liver, adipose
tissue, and whole-body [12]. Alternatively, peptidoglycan
from Gram-positive bacteria stimulates TLR2 and activates
innate immunity [13], and therefore the lack of such stimu-
lation may be expected to increase low-grade inflammation
due to the lack of regulatory immunity. Ampicillin is a broad-
spectrum antibiotic which can be used to target both Gram-
positive and Gram-negative bacteria. Ampicillin treatment
for longer periods, such as two-three weeks in lepob mice
[14], four weeks in wild-type nonmodified C57BL/6 mice
[15], and eight weeks in DIO Swiss mice [16], improves
glucose tolerance, whereas the narrow-spectrum antibiotic
erythromycin targeting mainly Gram-positive bacteria does
not seem to have any effect [15]. Consequently, it ismore likely
that low-grade inflammation causing glucose intolerance is
correlated to Gram-negative bacteria and subsequent LPS
and TLR4 stimulation rather than to Gram-positive bacteria
and subsequent TLR2 stimulation. This is also supported by
the fact that TLR4 deficientmice are resistant to the induction
of glucose intolerance through a high-fat diet (HFD) [17].The
impact on glucose tolerance in Ampicillin-treated wild-type
C57BL/6 mice is not combined with impact on growth or gut
regulatory immunology [15], whereas in the DIO Swiss mice,
Ampicillin in addition to improving glucose tolerance also
reduces the levels of insulin, TNF-𝛼, IL-6, and TLR4 activity
[16]. The difference between these two studies may be that
low-grade inflammation is actually not induced in wild type
C57BL/6mice, which are known to develop impaired glucose
tolerance spontaneously [18], whereas HFD in mice, as it has
been used in Swiss mice [16], is known to induce a low-grade
inflammation [19].Therefore, theremight be a higher number
of immune-active cells to impact on Ampicillin treatment in
HFD mice.
The mechanism behind improved glucose tolerance due
to broad-spectrumantibiotic treatmentmay simply be related
to a reduced transfer of LPS over an immature and permeable
gut. However, the gut may not be equally permeable at any
time of age [9]. All previous studies have initiated Ampicillin
treatment early in life and continued it throughout the study
[14–16]. The preweaned gut seems to be more permeable
than the weaned gut [20, 21], and therefore glucose tolerance
may only be induced with antibiotics if initiated early in
life. Furthermore, if the gut microbial impact on glucose
tolerance to a wide extent should be linked to the transfer of
LPS from gut to serum, the intolerance would return rather
quickly after terminating the antibiotic treatment, and there
would be no lasting effects to reveal in the immune system.
Consequently, the aim of this studywas to determinewhether
a specific time frame exists in which manipulation of the gut
microbiota by means of broad-spectrum antibiotic treatment
would have an impact on disease development, here shown as
glucose tolerance, andwhether early interventionwould have
a lasting effect.
2. Results
2.1. Animal Weights. At five weeks of age, no weight
differences could be demonstrated between the groups
(Figure 2(b)). At 11 weeks of age, bothHFD-fed groups of ani-
mals were significantly heavier than their LFD counterparts,
whereas no difference could be demonstrated between the
two HFD groups. At 16 weeks of age, a difference was found
only between the nontreated HFD group and the LFD group
(Figure 2(b)).
2.2. Glucose and Insulin. At five weeks of age, a significant
increase was found in oral glucose tolerance in Ampicillin-
treated HFD mice (Group 1; Ampicillin+/DIO+) compared
with nontreated HFD mice (Group 2; Ampicillin-/DIO+)
(AUC, 𝑃 = 0.0067; Figure 2(a)). However, at 11 weeks
of age, that is, six weeks after terminating the Ampicillin
treatment, the glucose tolerance in the Ampicillin-treated
HFD group (Group 1; Ampicillin+/DIO+) was significantly
lower compared to the low-fat diet (LFD) control animals
(Group 3; Ampicillin−/DIO−) (𝑃 = 0.04; Figure 2(a)).
Ampicillin treatment for four weeks from 12 to 16 weeks of
age did not cause any differences in oral glucose tolerance, but
the HFDmice treated with Ampicillin at an early age (Group
1A; Ampicillin 5w+ 16w−/DIO+) were still significantly less
glucose tolerant than low-fat fed mice (Group 3; Ampicillin
5w− 16 w−/DIO−) (𝑃 = 0.028; Figure 2(a)). Fasting insulin
levels were not significantly different between any group at
any point of measurement during the study. At six weeks
of age, the glycated hemoglobin (HbA1c) values of the
Ampicillin-treated HFD mice (Group 1; Ampicillin+/DIO+)
were significantly lower than the values of the nontreated
HFD mice (Group 3; Ampicillin−/DIO−) (𝑃 = 0.037;
Figure 2(c)), and this was still the case at 17 weeks of age
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Figure 2: (a) Oral glucose tolerance (mean and SEM, relative values). Statistics were calculated on areas under the curves (AUC) and showed
statistically significant differences between groups 1 (Ampicillin+/DIO+) and 2 (Ampicillin−/DIO+) at five weeks of age (𝑃 = 0.0067). At 11
weeks of age, no difference between the high-fat fed groups could be demonstrated, but differences between groups 1 (Ampicillin+/DIO+)
and 3 (Ampicillin−/DIO−) were now evident (𝑃 = 0.04). At 16 weeks of age, differences between the early Ampicillin-treated group 1A
(Ampicillin 5w+ 16w−/DIO+) and the low-fat fed group 3 (Ampicillin 5w− 16w−/DIO−) were still evident (𝑃 = 0.028). (b) At five weeks of
age, no difference between body weights could be demonstrated, whereas differences between the high-fat fed groups 1 (Ampicillin+/DIO+)
and 2 (Ampicillin−/DIO+) compared to the low-fat fed group 3 (Ampicillin−/DIO−) were evident at 11 weeks of age (𝑃 = 0.0028). At 16 weeks
of age, only a difference between the nontreated high-fat fed group 2B (Ampicillin 5w− 16w−/DIO+) and low-fat fed group 3 (Ampicillin 5w-
16w−/DIO−) could be demonstrated (𝑃 = 0.0159) (mean and SEM depicted). (c) Glycated hemoglobin (% HbA1c, mean and SEM) shows
differences between the high-fat fed groups 1 (Ampicillin+/DIO+) and 2 (Ampicillin−/DIO+) at six weeks of age (𝑃 = 0.037), whereas now
difference could be demonstrated at 12 weeks of age. At 17 weeks of age, differences were found between the early treated groups 1A (Ampicillin
5w+ 16w−/DIO+) and 1B (Ampicillin 5w+ 16w+/DIO+) and the late treated group 2A (Ampicillin 5w− 16w+/DIO+), respectively (𝑃 = 0.036;
𝑃 = 0.029).
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for the HFD mice treated with Ampicillin in early life (𝑃 =
0.036 for the mice treated once (Group 1A; Ampicillin 5w+
16w−/DIO+), and 𝑃 = 0.029 for those treated twice (Group
1B; Ampicillin 5w+ 16w+/DIO+)).
2.3. Plasma Cytokines and Lipopolysaccharides (LPS). In the
mice that were not treated with Ampicillin at any time, IL-6
was significantly lower in HFD mice compared to the values
of LFD mice at 17 weeks of age (𝑃 = 0.039). No other
differenceswere found in plasma cytokinesmeasured at study
termination (Figure 3; Table 1). TNF-𝛼 levels were measured,
but all measurements were below detection limit.
LPS levels were measured at six weeks of age and again
at 17 weeks of age. At no point in time significant differences
between any of the groups (Figure 4) were found.
2.4. Gut Microbiota. Cluster analysis of denaturing gradient
gel electrophoresis (DGGE) profiles obtained at five weeks of
age showed a similarity of 0% when comparing all animals.
At 11 weeks of age the overall similarity was 41%, and at 16
weeks of age the overall similarity was 23%.When comparing
different points in time for nontreated animals throughout
the study, a similarity of 43% was obtained for both HFD and
LFD mice.
Analysis of entry coordinates obtained from Principal
Component Analysis (PCA) plots showed a significant dif-
ference in gut microbiota at five weeks of age in relation
to both Ampicillin treatment (PC1: 𝑃 = 0.000, PC2: 𝑃 =
0.001; Figure 5(a)) and diet (PC1: 𝑃 = 0.000, PC3: 𝑃 =
0.05; Figure 5(c)), and this was also the case at 16 weeks of
age (Ampicillin PC1: 𝑃 = 0.000; Figure 5(b)) (Diet PC1:
𝑃 = 0.000; Figure 5(d)), whereas no differences could be
demonstrated during the period of no Ampicillin treatment,
that is, at 11 weeks of age, except for a borderline difference in
relation to diet (PC2: 𝑃 = 0.060).
2.5. Expression Analysis in Ileum. The expression of the
mRNA of both serum amyloid A (SAA) (𝑃 = 0.0012) and
interleukin 18 (IL-18) (𝑃 = 0.0014) was downregulated in
HFD mice (Figure 6(a)). Although some variation was seen
between the animals, both SAAmRNA (𝑃 = 0.032) and
TNFmRNA (𝑃 = 0.029) were found to be expressed two to
15 times more in mice treated with Ampicillin at five and 16
weeks of age compared tomice only treated late (Figure 6(b)).
Tumor necrosis ligand superfamily 15 (TNFSF15) mRNAwas
found to be significantly downregulated in the mice treated
with Ampicillin at five and 16 weeks of age compared to those
only treated in late life (𝑃 = 0.002; Figure 6(b)). Lactase
was upregulated threefold in the mice only treated with
Ampicillin early in life compared to the all other groups of
HFDmice, but the difference was only found to be significant
compared to those treated with Ampicillin twice (𝑃 = 0.044;
Figure 6(b)).
2.6. Flow Cytometric Analyses of Dendritic Cells and Regula-
tory T Cells. Higher percentages of CD11b positive dendritic
cells (CD11c+) were found systemically in the spleen from
HFDmice compared to the LFD mice (Figure 7(a)), whereas
a decrease in splenic dendritic cells expressing the tolerogenic
marker CD103 was seen in the same mice (Figure 7(d)). Fur-
thermore, both groups of HFD mice treated with Ampicillin
later in life were found to have a lower amount of tolerogenic
dendritic cells compared to the other groups independent of
an early lifeAmpicillin treatment (Figure 7(e)).No significant
differences were found in the Peyer’s patches, and no other
differences were detected among the dendritic and regulatory
T cells (FoxP3 positive) (Figure 7).
3. Discussion
Initiation of Ampicillin treatment from birth had a clearly
beneficial effect on glucose tolerance which was not the
case when these early treated mice were tested later in life,
although at 17 weeks of age theirHbA1cwas still lower. HbA1c
reflects long-term blood glucose and may at 17 weeks of age
still be under impact of the early life Ampicillin treatment.
It is also interesting to note that during the remaining part
of the study, the early treated mice were significantly less
glucose tolerant than the control group, which supports a
newly published observation that subtherapeutic antibiotic
therapy increased adiposity in young mice [22].
Three genes involved in inflammatory responses, namely,
TNF, TNFSF15, and SAA, were found to be differentially
expressed according to the time of Ampicillin treatment. In
mice the gene SAA2, which in this study was genetically
upregulated in treated mice, is expressed and induced prin-
cipally in the liver by the proinflammatory cytokines IL-
1, IL-6, and TNF-𝛼. Hepatic SAA1 and SAA2 are induced
up to a thousandfold in mice under acute inflammatory
conditions following exposure to LPS [23]. Also extra hepatic
expression of SAA in response to infection and inflammation
in pig and cattle has been reported [24, 25]. This, along with
TNFmRNA also being upregulated, supports that Ampicillin
treatment, although inducing an acute improvement in glu-
cose tolerance during treatment, actually leads to increased
inflammation and a subsequent risk of reduced glucose
tolerance after termination. However, in this study serum
levels of IL-6 and IL-1 did not differ in mice treated in early
life with Ampicillin compared to other mice on the HFD.
It could be hypothesized that Ampicillin treatment in
this crucial phase of developing regulatory immunity inter-
feres with the development of oral tolerance and therefore
increases the risk of an inflammatory response when the
gut bacteria reappear. Obesity in humans and HFD mice
has previously been linked to depletion of regulatory T cells
[26]. However, in another study, Ampicillin treatment did
not seem to have a major impact on the regulatory T or
NK cell related immunity [16]. Our study does not indicate
that regulatory T or dendritic cell compartments, neither
locally nor systemically, seem to play an important role in the
altered glucose tolerance induced by the early life Ampicillin
treatment. However, a shift in the ratio of CD11b positive
and CD103 positive dendritic cells in HFD mice indicates
that these may be of significance to the glucose intolerance
induced by HFD, whereas this does not seem to be the case
for regulatory T cells, at least not whenmonitored at 17 weeks
Journal of Diabetes Research 5
1A 1B 2A 2B 3
Groups
1A 1B 2A 2B 3
Groups
1A 1B 2A 2B 3
Groups
1A 1B 2A 2B 3
Groups
1A 1B 2A 2B 3
Groups
1A 1B 2A 2B 3
Groups
1A 1B 2A 2B 3
Groups
1A 1B 2A 2B 3
Groups
1A 1B 2A 2B 3
Groups
1A 1B 2A 2B 3
Groups
1A 1B 2A 2B 3
Groups
0
500
1000
1500
2000
2500
(p
g/
m
L)
(p
g/
m
L)
(p
g/
m
L)
(p
g/
m
L)
(p
g/
m
L)
(p
g/
m
L)
(p
g/
m
L)
(p
g/
m
L)
(p
g/
m
L)
(p
g/
m
L)
(p
g/
m
L)
IL-2
0
50
100
150
IL-4
IL-5 IL-6 IL-10
IL-12 (p70) IL-17 IL-18
0
10
20
30
40
IL-1𝛼
0
0
100
200
300
400
0
200
400
600
800
1000
0
10
20
30
40
0
20
40
60
0
20
40
60
80
2000
0
500
1000
1500
0
500
1000
1500
2000
4000
6000
INF𝛾 GM-CSF
Ampicillin 5w+ 16w−/DIO+
Ampicillin 5w+ 16w+/DIO+
Ampicillin 5w− 16w+/DIO+
Ampicillin 5w− 16w−/DIO+
Ampicillin 5w− 16w−/DIO−
Lower limit of detection
Figure 3: Levels of various plasma cytokines measured at week 17 at termination of the study (mean and SEM). IL-6 was statistically
significantly higher in the low-fat fed group 3 (Ampicillin 5w− 16w−/DIO−) compared to the nontreated high-fat fed group 2B (Ampicillin
5w− 16w−/DIO+) (𝑃 = 0.039). TNF𝛼 levels (not shown) were also measured, but all measurements were under detection sensitivity.
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Table 1: Serum cytokines in diet-induced obese C57BL/6 mice treated or not treated with Ampicillin from birth to five weeks of age, from 12
to 16 weeks of age, or both.
Group Ampicillin DIO 𝑁 IL-1a IL-2 IL-4
Early Late Median Minimum Maximum Median Minimum Maximum Median Minimum Maximum
1A + − + 10 80.845 28.35 591.01 31.44 2.91 66.11 2.17 0.35 31.05
1B + + + 10 61.96 7.85 591.01 32.61 4.4 53.17 3.26 0.35 22.25
2A − + + 6 100.32 28.76 664.78 32.27 4.4 124.6 0.35 0.35 5.49
2B − − + 4 112.92 45.67 2222.22 4.4 4.4 43.81 1.625 0.35 3.26
3 − − − 8 62.395 45.6 389.82 36.56 5.34 65.84 3.82 0.35 28.73
Group Ampicillin DIO 𝑁 IL-5 IL-6 IL-10
Early Late Median Minimum Maximum Median Minimum Maximum Median Minimum Maximum
1A + − + 10 214.27 2 57.4 37.55 1.1 136.14 155.045 48.06 874.79
1B + + + 10 87.08 32.08 60.14 34.3 1.1 374.97 246.91 70.73 1244.12
2A − + + 6 269.025 55.23 36.38 9.2 1.1 80.87 352.825 146.38 729.41
2B − − + 4 140.725 13.46 4.3 6.7a 1.1 12.3 205.345 114.05 1883.25
3 − − − 8 164.635 2 4.3 34.05a 1.1 51.72 403.235 130.14 642.39
Group Ampicillin DIO 𝑁 IL-12p70 IL-17 IL-18
Early Late Median Minimum Maximum Median Minimum Maximum Median Minimum Maximum
1A + − + 10 4.3 4.3 57.4 11.24 1.2 25.05 520.83 58.45 1386.39
1B + + + 10 4.3 4.3 60.14 9.21 0.73 28.9 58.45 58.45 1902.05
2A − + + 6 4.3 4.3 36.38 2.425 1.2 20.53 58.45 58.45 1939.3
2B − − + 4 4.3 4.3 4.3 3.485 2.22 4.97 58.45 58.45 4876.61
3 − − − 8 4.3 4.3 4.3 8.25 1.2 18.87 58.45 58.45 1939.3
Group Ampicillin DIO 𝑁 INF𝛾 TNF𝛼 GM-CSF
Early Late Median Minimum Maximum Median Minimum Maximum Median Minimum Maximum
1A + − + 10 44.675 5.56 252.73 1.05 1.05 1.05 5.45 5.45 49.69
1B + + + 10 35.04 3.03 444.26 1.05 1.05 1.05 5.45 5.45 24.7
2A − + + 6 35.085 17.95 436.95 1.05 1.05 1.05 5.45 3.74 24.7
2B − − + 4 36.99 24.64 1421.42 1.05 1.05 1.05 5.45 5.45 6.29
3 − − − 8 35.915 21.2 333.55 1.05 1.05 1.05 5.45 3.74 24.7
a
𝑃 = 0.039.
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of age. TNFSF15mRNA was significantly downregulated in
the ileum of mice treated twice with Ampicillin compared
to being treated only once. TNFSF15, also known as TL1A,
is a potential vascular endothelial cell growth inhibitor [27],
and it is related to inflammatory diseases of the gut, such as
inflammatory bowel disease (IBD) [28] and irritable bowel
syndrome (IBS) [29]. The expression of this inhibitor is
regulated by several members of the gut microbiota [30],
and therefore it is interesting, but not that surprising, that it
is downregulated in the animals receiving the most intense
Ampicillin treatment. Our observation that early life Ampi-
cillin treatment upregulates lactase in the gut is in accordance
with a study in which lactase also was upregulated in piglets
raised under germ-free conditions compared to conventional
piglets [31].
Ampicillin treatment clearly modified the gut microbiota
at both points in time of treatment, but these gut microbiota
changes did not seem to be lasting as therewere no differences
between the mice in the Ampicillin-free period.
The findings in the present study may speak in the
favour of the theory that LPS during early life diffuses
over a permeable mucosal barrier into the lamina propria
and serum and thereby induces a low-grade inflammation
through TNF-𝛼. The lack of impact on serum TNF-𝛼, which
we observed, may seem to speak against this, but this was
monitored at the end of the study and not during Ampicillin
treatment. Preweaning reduction of the levels of gut LPS
may, therefore, at this age improve glucose tolerance, while
LPS diffusion may decrease after weaning due to decreased
gut permeability [21]. In aged rats the permeability has then
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Figure 6: Significant differences in ileummRNA expression as revealed by qPCR in diet-induced obese C57BL/6mice treated or not treated
with Ampicillin from birth and until five weeks of age (1A; Ampicillin 5w+ 16w−/DIO+), from 12 to 16 weeks of age (2A; Ampicillin 5w−
16w+/DIO+), at both points in time (1B; Ampicillin 5w+ 16w+/DIO+), or not at all (2B; Ampicillin 5w− 16w−/DIO+), as well as low-fat fed
control mice (3; Ampicillin 5w− 16w−/DIO−). Interleukin 18 (IL 18), Lactase (Lct), serum amyloid A (Saa2), tumor necrosis factor (Tnf),
Tumor necrosis factor ligand superfamily 15 (Tnfsf15). (a): SAA (𝑃 = 0.0012), IL-18 (𝑃 = 0.0014). (b): Lct (𝑃 = 0.044), Tnf (𝑃 = 0.029), SAA
(𝑃 = 0.032), ∗∗Tnfsf15 (𝑃 = 0.002).
been shown to increase again [32]. Consequently, our study
only gives some indication of the impact on pre-weaned and
juvenile animals. It is also of importance that the impact
of the HFD on glucose tolerance seems to decline during
the study, which may, on the one hand, support the theory
of LPS diffusion in early life as an essential factor but on
the other hand leave less intolerance to be corrected by any
experimental treatment. C57BL/6 mice have a high insulin
secretory capacity and with age they will increase this to
reduce the impact of peripheral low-grade inflammation on
glucose intolerance [33]. This may also have been the case in
this study. The fact that glucose tolerance in general seems
to be lower at five weeks of age in this study may be due to
the very young age of the animals at this point in time. It
is recognised that stress due to handling of the animals may
result in increased blood glucose levels.
IL-18 is known to induce IFN-𝛾 production in natural
killer (NK) cells and certain T cells as a response to LPS
[34]. The HFD significantly downregulated mRNA coding
for SAA and IL-18 in the gut. This is surprising because SAA
is normally related to acute inflammation and the transport
of cholesterol to the liver, where it also plays a role in
various inflammatory diseases, such as atherosclerosis, and
rheumatoid arthritis [23]. On the other hand, SAA is known
to respond rapidly in the acute phase of inflammation, and it
may be a compensatory effect that it is downregulated in the
ileum if upregulated elsewhere in the organism over a longer
period of time. The dietary impact on SAA corresponds to
the observation that its inducer IL-6 was also significantly
lower in plasma of the mice on the high-fat diet. The fact
that IL-6 was higher in the low-fat fed animals compared to
the high-fat fed animals was an unexpected finding as obesity
and type 2 diabetes are connected to an increase of low-grade
inflammatory cytokine such as IL-6.
To further study the impact of Ampicillin treatment on
glucose tolerance, it would be valuable in future studies also
to collect immunological data in the youngmice during treat-
ment, although this obviously calls for another experimental
design inwhich animals are killed for gut sampling during the
course of the study. It would also be of importance to correlate
the level of gut permeability to the level of glucose intolerance,
and it would be of interest to study even older animals.
In conclusion, changing glucose tolerance by means of
antibiotic treatment in mice seems primarily possible in the
very early life, and the improvement in tolerance disappears
when treatment is terminated.
4. Materials and Methods
4.1. Animals. Experiments were carried out in accordance
with the European Union directive 86/609 on the Protection
of Vertebrate Animals used for Experimental and Other
Scientific Purposes, and the Danish Animal Experimentation
Act number 1306 from November 23, 2007 which
follows principles similar to “Principles of laboratory
animal care” (NIH publication no. 85–23, revised 1985;
http://grants1.nih.gov/grants/olaw/references/phspol.htm).
The study was approved by the Animal Experiments
Inspectorate, Ministry of Justice, Denmark.
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Figure 7: Flow cytometric analyses of lymphocytes isolated from the spleen, mesenteric lymph nodes (MLN), and Peyer’s patches (PP).
((a)–(c)) Percentages of CD11b positive dendritic cells (CD11c+). ((d)–(f)) Percentages of tolerogenic CD103 positive dendritic cells. ((g)–(i))
Percentages of FoxP3 positive regulatory T cells (CD4+). High-fat diet (HFD) induced C57BL/6mice treated with Ampicillin from birth and
until five weeks of age (1A; Ampicillin 5w+ 16w−/DIO+), or from birth and until five weeks of age followed by Ampicillin treatment from
12 to 16 weeks of age (1B; Ampicillin 5w+ 16w+/DIO+), or only from 12 to 16 weeks of age (2A; Ampicillin 5w− 16w+/DIO+) are illustrated
together with untreated HFD induced mice (2B; Ampicillin 5w− 16w−/DIO+) and untreated control mice (3; Ampicillin 5w− 16w−/DIO−).
Error bars represent the SEM. ∗(𝑃 < 0.05), ∗∗(𝑃 < 0.01).
Twenty-five presumed pregnant female C57BL/6NTac
mice (Taconic Europe A/S, Ejby, Denmark) were divided
into three groups. The pregnant mice gave birth to 40 male
pups, which were individually earmarked (number 1–40) and
randomized into cages with two to four animals in each
group. The study continued for a total of 17 weeks counting
from birth of the male pups. The animals were weighed once
weekly from weaning. Prior to being killed by cervical dislo-
cation at 17 weeks of age the animals were anaesthetized with
Hypnorm/Dormicum mixture (VetPharm Ltd., Sherburn in
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Elmet, Leeds, UK; Roche A/S, Hvidovre, Denmark) (0.2mL
SC in a 1 : 1 : 2 water solution). The animals were daily sub-
jected to visual control, and by signs of illness or misthriving
the affiliated veterinarian was consulted.
4.2. Diets. The animals in groups 1 and 2 were fed a high-
fat diet (HFD) throughout the study (60% energy from fat,
D12492, Research Diets Inc., New Brunswick, NJ, USA),
whereas the animals in group 3 acted as a low-fat control
group receiving a low-fat diet (LFD) throughout the study
(10% energy from fat, C12450B, Research Diets Inc., New
Brunswick, NJ, USA) (Figure 1). The feed was weighed and
changed twice weekly.
4.3. Antibiotic Treatment. The animals in group 1 (𝑛 = 21)
received the broad-spectrum antibiotic Ampicillin in their
drinking water (1 g/L) (Ampivet vet., Boehringer Ingelheim,
Copenhagen, Denmark) from three days prior to birth of the
pups until the pups reached five weeks of age. The animals
in groups 2 and 3 received pure drinking water (tap water)
during this period (group 2 (𝑛 = 11), group 3 (𝑛 = 8)).
From five weeks of age all animals received pure drinking
water until week 12, where group 1 was subdivided into
groups 1A (𝑛 = 10) and 1B (𝑛 = 11), and group 2 was
subdivided into groups 2A (𝑛 = 6) and 2B (𝑛 = 5). The
animals in groups 1B and 2A were shifted to water containing
Ampicillin for the rest of the study. Groups 2B and 3 (𝑛 =
8) acted as HFD and LFD control groups, respectively, and
received pure drinkingwater throughout the study.Waterwas
changed twice weekly during periods of antibiotic treatment
and once weekly during periods with no antibiotic treatment
(Figure 1).
4.4. Glucose, Insulin, and HbA1c. Oral glucose tolerance test
(OGTT) was performed at the end of the first treatment
period (week 5), prior to the second treatment period (week
11) and at the end of the second treatment period (week
16). The mice were fasted overnight for 10 hours prior to
the procedure. A baseline blood glucose level (𝑡 = 0)
was measured by a Freestyle Mini Glucometer (Hermedico,
Copenhagen, Denmark), and the mouse was immediately
after gavaged with a glucose solution according to weight
(Amgro I/S, Copenhagen, Denmark, concentration 500 g/l.,
dose 4mL/kg). Blood glucose was then measured at 𝑡 = 30,
60, 90, 120, and 180min after gavage.
At weeks 6, 12, and 17 mouse plasma samples were
analysed for insulin content using the Ultra sensitive Rat
Insulin ELISA Kit (Crystal Chem, Downer’s Grove, USA)
with the modifications that sample volume was reduced to
5 𝜇L and that in-house rat insulin standards, prepared using
heat-treated rat plasma, were used. Glycated hemoglobin
(HbA1c) was measured on a Siemens DCAVantage Analyzer
(Siemens Healthcare Diagnostics, Ballerup, Denmark) by
collection of 1 𝜇L full blood from a puncture in the tail vein
in the supplied collection cassette.
4.5. Plasma Cytokines and Lipopolysaccharides (LPS). The
plasma cytokines IL-1𝛼, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17,
TNF𝛼, INF𝛾, and GM-CSF were measured by means of the
Mouse Th1/Th2 10plex FlowCytomix Multiplex kit (Bender
MedSystems, Vienna, Austria) in combination with two sim-
plex kits; Mouse IL-12 (p70) FlowCytomix Simplex and IL-18
FlowCytomix Simplex (both Bender MedSystems). The assay
was performed according tomanufacturer’s instructions.The
analysis was run on a BD FacsCanto Flow Cytometer (BD
Biosciences, Albertslund, Denmark) and processing of data
was performed using the FlowCytomixTM Pro 2.3 Software
(Bender MedSystems).
Plasma contents of LPS were measured using the Pyro-
Gene Recombinant Factor C Endotoxin Detection System
(Lonza, Basel, Switzerland). The test utilizes recombinant
factor C (rFC) which is an endotoxin-sensitive protein in
combination with a fluorogenic substrate. The assay was
performed according tomanufacturer’s instructions andfluo-
rescence was measured before and after one-hour incubation
at 37∘C on a SpectraMax Plus 384 plate reader (Molecular
Devices Inc., CA, USA).
4.6. Gut Microbiota. Fecal samples obtained aseptically at
five, 11, and 16 weeks of age were analysed by means
of DGGE as previously described [35]. In brief, bacterial
DNA was extracted using the QIAamp DNA Stool Mini
Kit (Qiagen, Hilden, Germany). Samples were homogenized
prior to extraction using a FastPrep FP120 Cell Disrupter
(QBiogene, MP Biomedicals, France) for 45 sec at 6m/sec.
Quality and concentration of the extractedDNAwere verified
on a NanoDrop 1000 Spectrophotometer (Thermo Scientific,
USA). Genetic material was then amplified by Polymerase
Chain Reaction (PCR), using primers specific to the V3
region of the 16S rRNA gene. Subsequently, genetic material
was separated by means of DGGE on a polyacrylamide gel
containing a 30%–65% chemical gradient (100% corresponds
to 7M urea and 40% formamide). DGGE profiles were anal-
ysed using BioNumerics version 4.5 (Applied Maths, Sint-
Martens-Latem, Belgium) for cluster analysis (dice similarity
coefficient with a band position tolerance and optimization of
1% using the unweighted pair Group method with arithmetic
averages clustering algorithm (UPGMA)) and principal com-
ponent analysis (PCA).
4.7. Gene Expression in Ileum. The ileum was sampled and
frozen with liquid nitrogen immediately after cervical dislo-
cation. Approximately 20–30mg of the frozen tissue was then
homogenized in 1mL QIAzol Lysis Reagent (Qiagen) using
gentleMACSDissociator (Milteny Biotec, GmbH, Germany).
Total RNA was extracted using RNeasy lipid Tissue midi
kit (Qiagen), and all samples were treated with RNase-free
DNase (Qiagen) (manufacturer’s instructions). RNA purity
was assessed using UV absorption spectrums including
OD 260/280 and OD 260/230 ratios on a NanoDrop ND-
1000 spectrophotometer (Saveen and Werner AB, Limhamn,
Sweden). RNA integrity (RIN), which was between 6.1 and 8
for all samples, was measured on an Agilent 2100 Bioanalyzer
(Agilent Technologies, Nærum, Denmark) using the RNA
6000 Nano Kit. Extracted RNA was converted into cDNA
by reverse transcription of 500 ng total RNA using the
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Table 2: Genes tested by qPCR in ileum tissue of in C57BL/6mice treated or not treated with Ampicillin from birth to five weeks of age, from
12 to 16 weeks of age, or both.
Gene symbol Gene Amplification efficiency (%) Sequence 5󸀠-3󸀠 Accession number
Actb Beta-actin 99 F CCCTAAGGCCAACCGTGAAA NM 007393.3
R CAGCCTGGATGGCTACGTAC
Alpi Alkaline phosphatase, 93 F TCCTAAAGGGGCAGTTGGAA NM 001081082.1
Intestinal R ACCTGTCTGTCCACGTTGTA
B2m Beta-2 microglobulin 100 F CTGGTGCTTGTCTCACTGAC NM 009735.3
R GGTGGGTGGCGTGAGTATA
Gusb Glucuronidase, beta 101 F AGTATGGAGCAGACGCAATCC NM 010368.1
R ACAGCCTTCTGGTACTCCTCA
Hp Haptoglobin 96 F TATCGCTGCCGACAGTTCTAC NM 017370.2
R CTCTCCAGCGACTGTGTTCA
Hprt1 Hypoxanthine 97 F CAGTACAGCCCCAAAATGGTTA NM 013556.2
Phosphoribosyltransferase R AGTCTGGCCTGTATCCAACA
Il18 Interleukin 18 98 F CAAAGAAAGCCGCCTCAAAC NM 008360.1
R GACGCAAGAGTCTTCTGACA
Il1a Interleukin 1 alpha 103 F AGATGGCCAAAGTTCCTGAC NM 010554.4
R AGAGATGGTCAATGGCAGAAC
Lct Lactase 92 F TGTCCTAGCCTACAACCTCAAC NM 001081078
R AGCGGTCTGTAATGGAAGCA
Muc2 Mucin 2 93 F TATGCCAGGCCAGGAGTTTA NM 023566.2
R GCAAGGCAGGTCTTTACACA
Nfkbia Nuclear factor of kappa, alpha 96 F GAGCGAGGATGAGGAGAGCTA NM 010907.2
R GGCCTCCAAACACACAGTCA
Rpl13a Ribosomal protein L13A 103 F AGGTTACGGAAACAGGCAGAA NM 009438.
R CAGGAGTCCGTTGGTCTTGA
Saa Serum amyloid A 102 F GAGTCTGGGCTGCTGAGAAA NM 011314.2
R ATGGTGTCCTCGTGTCCTCT
Tbp TATA box binding protein 100 F ACCAGAACAACAGCCTTCCA NM 013684.3
R AAAGATGGGAATTCCAGGAGTCA
Tgfb1 Transforming growth factor, beta 1 98 F GCTGCGCTTGCAGAGATTAA NM 011577.1
R GTAACGCCAGGAATTGTTGCTA
Tlr4 Toll-like receptor 4 98 F GTTCTTCTCCTGCCTGACAC NM 021297.2
R GCTGAGTTTCTGATCCATGCA
Tnf Tumor necrosis factor 95 F CAAATGGCCTCCCTCTCATCA NM 013693.2
R TGGGCTACAGGCTTGTCAC
Tnfsf15 Tumor necrosis factor 97 F GCAAGCCGAGAGCACAC NM 177371.3
Superfamily, member 15 R CCATCCCTAGGTCATGTTCCC
QuantiTECT Reverse Transcription kit (Qiagen) containing
a mix of random primers and oligo-dT (manufacturer’s
instructions). Two separate cDNA reactions were performed
for each sample. cDNA was diluted 1 : 6 in low EDTA TE-
buffer (VWR-Bie & Berntsen) prior to preamplification,
which was completed using TaqMan PreAmp Master Mix
(Applied Biosystems, Foster City, CA). A 200 nM pooled
primer mix was prepared combining each primer used in
the present study. TaqMan PreAmp Master Mix (5 𝜇L) was
mixed with 2.5 𝜇L 200 nM pooled primer mix and 2.5 𝜇L
diluted cDNA and incubated at 95∘C in 10min, followed by 16
cycles of 95∘C in 15 sec and 60∘C in 4min. Preamplified cDNA
was diluted at least 1 : 4 in low EDTA TE-buffer (VWR).
Quantitative PCR (qPCR) primers were provided using the
DELTAgene assay design service (FluidigmCorporation, San
Francisco, CA, USA) (Table 2). All primers were designed
over introns. Primer amplification efficiencies and dynamic
range were acquired from standard curves constructed from
dilution series of highly responding samples. qPCR was
performed in the 48.48 Dynamic Array Integrated Fluidic
Circuits (Fluidigm) combining 48 preamplified samples with
48 primer sets for 2304 simultaneous qPCR reactions as
previously described [36]. qPCR was performed in the
BioMark real-time PCR instrument (Fluidigm Corporation),
and the following cycle parameter was used: 2min at 50∘C,
10min at 95∘C, followed by 35 cycles with denaturing for
15 sec. at 95∘C and annealing/elongation for 1min at 60∘C.
Melting curves were generated after each run to confirm a
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single PCRproduct (from60∘C to 95∘C, increasing 1∘C/3 sec).
Reactions were performed in duplicates (cDNA replicates).
No template controls (NTC) were included to indicate
potential problems with nonspecific amplification or sam-
ple contaminations. Nonreverse transcriptase controls were
included to assess potential DNA contamination. Relative
concentrations of target mRNAwere assigned using standard
curves constructed from three separate dilution series of
highly responding samples (cDNA dilution 1 : 3, 1 : 15, 1 : 75,
1 : 375, 1 : 1875, and 1 : 9375). Data were acquired using the
Fluidigm Real-Time PCR Analysis software 3.0.2 (Fluidigm
Corporation).
4.8. Flow Cytometry. Cells were isolated from spleen, mesen-
teric lymph node (MLN), and Peyer’s patches (PP) by
aseptically squeezing the fresh organs in PBS between two
microscope slides and subsequently passing the suspension
through a 70𝜇m cell strainer. Cell suspensions were stored
on ice at all times. Spleen cells were resuspended in red
blood cell lysis (ACK) buffer (0.15MNH
4
Cl, 10mMKHCO
3
,
1 mM EDTA monosodium pH 7.3) and incubated for six
min. Subsequently, cells were washed and resuspended in
PBS. Cells were surface stained for dendritic cell and T-cell
markers and with appropriate isotype control antibodies. All
antibodies (anti-mouse CD4, CD11c, CD11b, CD103, FoxP3)
were purchased from eBioscience (San Diego, CA, USA). For
the regulatory T-cell staining the cell was subsequently fixed,
permeabilized, and intracellular Foxp3 stained according to
the manufacturer’s protocol. Analysis was performed using
an Accuri C6 flow cytometer (Accuri Cytometers Inc., Ann
Arbor, MI, USA).
4.9. Statistics. Normality distribution of the data was mea-
sured with Anderson-Darling’s normality test considering 𝑃
values less than 0.05 significant (Minitab, Coventry, UK).
Statistical analysis of OGTT was performed on area under
the curve (AUC) using Statistica (Statsoft, Tulsa, OH, USA)
and statistical significance evaluated by two-way repeated
measures ANOVA followed by post hoc analysis using
Student’s t-test in case of significant effects. For analysis
of insulin, HbA1c, plasma cytokines, LPS, and PCA data,
GraphPad Prism version 5 (GraphPad Software, San Diego,
CA, USA) was used and the statistical significance evalu-
ated by one-way ANOVA (Kruskal-Wallis test on data that
did not assume Gaussian distributions) and Student’s t-test
(Mann-Whitney test on data that did not assume Gaussian
distributions). Values below detectable limits (insulin and
cytokinemeasurement kits) were given the value of half of the
lover limit of quantification (1/2 LLOQ). For analysis of data
from expression analysis of the ileum, data preprocessing,
normalisation, relative quantification, and statistics were
performed using GenEx5 (MultiD, Go¨teborg, Sweden). Data
was log
2
transformed for approaching normal distribution
prior to t-test (2-tailed, unpaired). Gene expression was
considered to be significantly different if the 𝑃 value < 0.05
and fold change > ±2.0. For analysis of FACS data, ANOVA
followed by t-test for significant differences between groups
was applied (Minitab).
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